Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
Reason given: the study drug could not be obtained
Key facts
- Where
- Charlottesville, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- University of VirginiaCharlottesville, United StatesNo longer taking part
Trial details
- Who runs it
- University of Virginia
- Trial code
- NCT04133922
- Record updated
- 22 March 2022
- Original description
GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle oxygenationRead full original descriptionShow less
GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle oxygenation
Inclusion: History of type 1 diabetes, duration > 1 year; Age 18-40 years; HbA1c < 8.5%; BMI >/=18, <30 kg/m2; Using insulin for diabetes treatment only; On stable regimen of non-diabetic medications for the last 6 months, excluding oral contraceptives (OCP); All screening labs within normal limits or not clinical significant.
Exclusion: Pregnancy or currently breastfeeding 2) Smoking history within 6 months 3) History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) 4) Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers) 5) OCP use within 3 months or 1 month if menses has subsequently occurred 6) Known hypersensitivity to perflutren (contained in Definity© contrast) 7) Screening O2 saturation<90% 8) Anemia (hemoglobin <12 g/dL in women, hemoglobin <13 g/dL in men) 9) Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days; -.